Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes.

ABSTRACT:

Background

Myasthenia is a condition in which neuromuscular transmission is affected by antibodies against neuromuscular junction components (autoimmune myasthenia gravis, MG; and neonatal myasthenia gravis, NMG) or by defects in genes for neuromuscular junction proteins (congenital myasthenic syndromes, CMSs). Clinically, some individuals seem to benefit from treatment with ephedrine, but its effects and adverse effects have not been systematically evaluated.

Objectives

To assess the effects and adverse effects of ephedrine in people with autoimmune MG, transient neonatal MG, and the congenital myasthenic syndromes.

Search methods

On 17 November 2014, we searched the Cochrane Neuromuscular Disease Group Specialized Register, the Cochrane Central Register of Controlle

SUBMITTER: Vrinten C 

PROVIDER: S-EPMC7387729 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature